- Charles River’s total revenue for the second quarter is $1.03 billion, surpassing estimates with a 0.6% year-over-year increase.
- The Research Models & Services segment generated $213.3 million in revenue, up 3.3% year-over-year, and exceeded the expected $206.9 million.
- Discovery & Safety Assessment (DSA) revenue was $618 million, a decrease of 1.5% year-over-year, but still above the estimate of $589.4 million.
- The Manufacturing Solutions division saw revenue of $200.8 million, marking a 4.4% increase year-over-year, beating forecasts of $188.1 million.
- Adjusted earnings per share (EPS) stood at $3.12.
- James C. Foster, Chair, President, and CEO, mentioned signs of stabilizing biopharmaceutical demand and progress in organic revenue growth.
- Foster highlighted strong second-quarter financial performance, particularly in the DSA segment.
- Analyst ratings include 5 buy recommendations, 12 holds, and 1 sell suggestion.
“`
A look at Charles River Laboratories Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Charles River Laboratories International, Inc., a company specializing in research tools and support services for drug discovery and development, has received a mix of Smart Scores in its various aspects. While the company scored high in momentum with a score of 4, indicating a strong positive trend, its values, dividend, growth, and resilience scores were moderate to low. The value score of 3 suggests a fair valuation, while the dividend score of 1 implies a lower dividend yield. In terms of growth and resilience, Charles River Laboratories scored 2 in each category, highlighting room for improvement in these areas. Overall, the company’s strong momentum could potentially drive its long-term performance in the market.
As Charles River Laboratories continues to provide essential animal research models for drug discovery and development, its performance in the market may be influenced by its overall Smart Scores. With a diverse customer base that includes pharmaceutical and biotechnology companies, hospitals, and academic institutions, the company plays a crucial role in supporting the advancement of new drugs, devices, and therapies. While there are areas for improvement in terms of value, dividend, growth, and resilience, the company’s solid momentum score suggests a positive outlook for its long-term prospects in the industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
